Startups
Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug called Bisantrene.
Overview
Location
Australia, New South Wales, Sydney
Employees
11-50
Phone
+61 3 9098 8750
Founded date
2011
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 10, 2023 | Race executes global license agreement with City of Hope to access FTO IP | Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States. Under the agreement, Race will exclusively secure rights to a City of Hope patent application ... |
| Sep 30, 2021 | Zantrene® kills melanoma cancer cells that overproduce FTO | Zantrene® at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells Results are h... |
| Jul 11, 2017 | Race Oncology and Swiss-based start-up enter into a joint venture | The Race Immunotherapeutics joint venture will be a 50:50 partnership between Race and TargImmune, and all new intellectual property created by RITX will be equally co-owned by the parties through their ownership of the joint venture. RITX ... |
Reviews 0
FAQ about Race Oncology
When was Race Oncology founded?
Race Oncology was founded in 2011.
What has the press written about Race Oncology?
Parsers VC has collected 4 articles mentioning Race Oncology, among them “Race executes global license agreement with City of Hope to access FTO IP” (Jul 10, 2023) and “Zantrene® kills melanoma cancer cells that overproduce FTO” (Sep 30, 2021).
Is Race Oncology still active?
Yes, Race Oncology is active; its latest activity on Parsers VC dates from Sep 30, 2021.